William Blair Reaffirms Outperform Rating for Biodesix (NASDAQ:BDSX)

Biodesix (NASDAQ:BDSX)‘s stock had its “outperform” rating reissued by research analysts at William Blair in a note issued to investors on Tuesday,RTT News reports. William Blair also issued estimates for Biodesix’s Q1 2026 earnings at ($0.05) EPS, Q2 2026 earnings at ($0.03) EPS, Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at ($0.03) EPS and FY2026 earnings at ($0.14) EPS.

Biodesix Price Performance

Biodesix stock opened at $0.87 on Tuesday. The business’s 50-day simple moving average is $1.09 and its 200 day simple moving average is $1.41. The stock has a market cap of $126.56 million, a price-to-earnings ratio of -2.23 and a beta of 1.10. Biodesix has a 12-month low of $0.64 and a 12-month high of $2.04. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30.

Biodesix (NASDAQ:BDSX) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. The business had revenue of $20.43 million for the quarter, compared to analysts’ expectations of $19.92 million. Biodesix had a negative return on equity of 275.79% and a negative net margin of 66.84%. As a group, research analysts anticipate that Biodesix will post -0.35 earnings per share for the current year.

Insider Buying and Selling at Biodesix

In other Biodesix news, CEO Scott Hutton sold 83,660 shares of the stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total value of $76,967.20. Following the transaction, the chief executive officer now owns 701,947 shares of the company’s stock, valued at approximately $645,791.24. This represents a 10.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have sold 128,702 shares of company stock valued at $118,406. 69.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Biodesix

Hedge funds have recently added to or reduced their stakes in the stock. Balyasny Asset Management L.P. acquired a new position in Biodesix in the fourth quarter valued at about $29,000. Barclays PLC raised its position in shares of Biodesix by 1,140.5% during the third quarter. Barclays PLC now owns 23,036 shares of the company’s stock worth $41,000 after purchasing an additional 21,179 shares during the period. Boothbay Fund Management LLC acquired a new stake in shares of Biodesix during the fourth quarter worth about $52,000. MYDA Advisors LLC acquired a new stake in shares of Biodesix during the fourth quarter worth about $76,000. Finally, Cubist Systematic Strategies LLC raised its position in shares of Biodesix by 385.9% during the fourth quarter. Cubist Systematic Strategies LLC now owns 51,024 shares of the company’s stock worth $78,000 after purchasing an additional 40,524 shares during the period. Institutional investors and hedge funds own 20.96% of the company’s stock.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.